|
|
TTD Drug ID:
DNC006022
Drug
Information |
Name | N-(4-morpholinophenyl)docos-13-enamide | Indication | Not Available | Experimental | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
| InChI | 1S/C32H54N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20 -21-32(35)33-30-22-24-31(25-23-30)34-26-28-36-29-27-34/h9-10,22-2 5H,2-8,11-21,26-29H2,1H3,(H,33,35)/b10-9- | InChIKey | BNCLSGYMSOUADZ-KTKRTIGZSA-N | Canonical SMILES | CCCCCCCCC=CCCCCCCCCCCCC(=O)NC1=CC=C(C=C1)N2CCOCC2 | Isomeric SMILES | CCCCCCCC/C=C\CCCCCCCCCCCC(=O)NC1=CC=C(C=C1)N2CCOCC2 | Target | Cannabinoid CB1 receptor |  | Inhibitor | [1] | Ref 1 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. Epub 2005 Oct 6.New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|